Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioCorRx ( (BICX) ) has shared an update.
On March 26, 2026, BioCorRx Inc. entered into a stock exchange agreement with three director-shareholders under which they transferred a total of 1,215 shares of BioCorRx Pharmaceuticals Inc., representing about 12.15% of the subsidiary’s outstanding common stock, to the parent company. In return, BioCorRx Inc. issued an aggregate of 2,263,371 restricted common shares as the sole consideration, with the exchange closing on March 27, 2026.
The transaction, approved by the board on February 25, 2026 under the company’s related-party transaction policy, is part of a broader plan of reorganization intended to give BioCorRx Inc. tax-efficient control of its subsidiary under U.S. tax code reorganization provisions. The private, non-public issuance to accredited investors, supported by registration rights for the new parent shares, further consolidates ownership of the subsidiary and may enhance strategic flexibility without immediate cash outlay or public offering dilution.
The most recent analyst rating on (BICX) stock is a Hold with a $0.40 price target. To see the full list of analyst forecasts on BioCorRx stock, see the BICX Stock Forecast page.
Spark’s Take on BICX Stock
According to Spark, TipRanks’ AI Analyst, BICX is a Neutral.
The score is held down primarily by very weak financial performance (ongoing losses, cash burn, and negative equity). Technical indicators are comparatively supportive with price above major moving averages and a positive MACD, but stretched momentum (stochastic at 100) adds near-term risk. Valuation remains unattractive due to unprofitability (negative P/E) and no dividend support.
To see Spark’s full report on BICX stock, click here.
More about BioCorRx
BioCorRx Inc., a Nevada corporation, operates through BioCorRx Pharmaceuticals Inc., its majority-owned pharmaceutical subsidiary. The company is focused on reorganizing its corporate structure to consolidate control of its subsidiary, positioning itself for greater strategic and operational alignment within its healthcare and life sciences activities.
Average Trading Volume: 9,599
Technical Sentiment Signal: Hold
Current Market Cap: $9.47M
For a thorough assessment of BICX stock, go to TipRanks’ Stock Analysis page.